| Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis R Beall, R Kuhn PLoS medicine 9 (1), e1001154, 2012 | 189 | 2012 |
| Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period A Sarpatwari, RF Beall, A Abdurrob, M He, AS Kesselheim Health Affairs 37 (5), 732-737, 2018 | 53 | 2018 |
| Is patent “evergreening” restricting access to medicine/device combination products? RF Beall, JW Nickerson, WA Kaplan, A Attaran PLoS One 11 (2), e0148939, 2016 | 50 | 2016 |
| Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997 B Sahragardjoonegani, RF Beall, AS Kesselheim, A Hollis Journal of pharmaceutical policy and practice 14, 1-8, 2021 | 42 | 2021 |
| Pre-market development times for biologic versus small-molecule drugs RF Beall, TJ Hwang, AS Kesselheim Nature Biotechnology 37 (7), 708-711, 2019 | 36 | 2019 |
| Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement RF Beall, R Kuhn, A Attaran Health Affairs 34 (3), 493-501, 2015 | 30 | 2015 |
| Modes of delivery in preventive intervention studies: a rapid review RF Beall, N Baskerville, M Golfam, S Saeed, J Little European journal of clinical investigation 44 (7), 688-696, 2014 | 30 | 2014 |
| A method for approximating future entry of generic drugs RF Beall, JJ Darrow, AS Kesselheim Value in Health 21 (12), 1382-1389, 2018 | 29 | 2018 |
| Patent term restoration for top-selling drugs in the United States RF Beall, JJ Darrow, AS Kesselheim Drug Discovery Today 24 (1), 20-25, 2019 | 25 | 2019 |
| Tertiary patenting on drug–device combination products in the United States RF Beall, AS Kesselheim Nature Biotechnology 36 (2), 142-145, 2018 | 25 | 2018 |
| A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications SM Baxi, R Beall, J Yang, TK Mackey Globalization and Health 15, 1-14, 2019 | 23 | 2019 |
| COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022 B Lau, M Tadrous, C Chu, L Hardcastle, RF Beall Cmaj 194 (23), E801-E806, 2022 | 19 | 2022 |
| The characteristics of patents impacting availability of biosimilars VL Van de Wiele, RF Beall, AS Kesselheim, A Sarpatwari Nature Biotechnology 40 (1), 22-25, 2022 | 18 | 2022 |
| Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines RF Beall, JW Nickerson, A Attaran Open Medicine 8 (4), e130, 2014 | 18 | 2014 |
| The global intellectual property ecosystem for insulin and its public health implications: an observational study WA Kaplan, RF Beall Journal of Pharmaceutical Policy and Practice 10, 1-9, 2017 | 17 | 2017 |
| Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020: Study examines patents and regulatory exclusivities on inhalers for asthma and COPD from 1986 … WB Feldman, D Bloomfield, RF Beall, AS Kesselheim Health Affairs 41 (6), 787-796, 2022 | 15 | 2022 |
| Patents and regulatory exclusivities on GLP-1 receptor agonists R Alhiary, AS Kesselheim, S Gabriele, RF Beall, SS Tu, WB Feldman JAMA 330 (7), 650-657, 2023 | 13 | 2023 |
| First‐line pharmacotherapy for incident type 2 diabetes: prescription patterns, adherence and associated costs DJT Campbell, DB Campbell, Y Ogundeji, F Au, R Beall, PE Ronksley, ... Diabetic Medicine 38 (9), e14622, 2021 | 13 | 2021 |
| The generic drug industry embraces a faster, cheaper pathway for challenging patents JJ Darrow, RF Beall, AS Kesselheim Applied Health Economics and Health Policy 17, 47-54, 2019 | 13 | 2019 |
| Insulin Patent Profile W Kaplan, R Beall Amsterdam: Health Action International, 2016 | 13 | 2016 |
Aaron KesselheimProfessor of Medicine, Harvard Medical School & Brigham and Women's Hospital在 partners.org 的电子邮件经过验证
